[ad_1]
A leading scientist behind the AstraZeneca vaccine has said COVID-19 booster shots may not be necessary for the majority of people, according to an article published Thursday by The Telegraph.
Sarah Gilbert, professor of vaccinology at the University of Oxford, told the Telegraph that immunity to the vaccine “lasts well in the majority of people,” even against the delta variant, but Gilbert said she believed that ‘a third injection may be necessary for the elderly. or immunocompromised.
Mass booster program is unnecessary, says scientist behind AstraZeneca vaccine https://t.co/cbJh7yNmQE
– Daily Mail Online (@MailOnline) September 10, 2021
“As the virus spreads between people, it mutates, adapts and evolves, like the delta variant. With these outbreaks, we want to stop this as quickly as possible, ”Gilbert told The Telegraph.
“We will look at each situation; the immunocompromised and the elderly will receive boosters. But I don’t think we need to stimulate everyone, ”she said.
Gilbert’s remarks come as the Joint Committee on Vaccination and Immunization, Britain’s advisory committee on vaccines, is set to decide whether citizens should receive a third dose of COVID-19 vaccine, according to the Associated Press. (“Natural Immunity Is Really Better”: New Israeli Study Fuels Debate Over Vaccination Versus Natural Immunity)
The British medical regulator on Thursday approved the Pfizer and AstraZeneca vaccines as boosters, according to The Telegraph. British health officials said on September 1 that people with weak or compromised immune systems could receive the third injection, according to Reuters.
Gilbert argues that the global priority right now should be to send vaccines to countries in short supply, according to the Telegraph.
“We need to vaccinate countries where few populations have been vaccinated so far,” Gilbert told The Telegraph.
“We need to do better in this regard. The first dose has the most impact, ”added Gilbert.
Content created by The Daily Caller News Foundation is available free of charge to any eligible news publisher who can provide a large audience. For licensing opportunities of our original content, please contact [email protected].
[ad_2]
Source link